Advertisement

Table of Contents

Masters of Immunology

Cancer Immunology at the Crossroads: Experimental Immunotherapies

Meeting Report

Cancer Immunology Miniatures

  • Cancer Immunology Miniatures
    Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies
    Gregory L. Beatty, Andrew R. Haas, Marcela V. Maus, Drew A. Torigian, Michael C. Soulen, Gabriela Plesa, Anne Chew, Yangbing Zhao, Bruce L. Levine, Steven M. Albelda, Michael Kalos and Carl H. June
    Cancer Immunol Res February 1 2014 2 (2) 112-120; DOI:10.1158/2326-6066.CIR-13-0170

    Beatty, Haas, and colleagues report antitumor activity in two patients treated with autologous T cells transfected with mRNA encoding a chimeric antigen receptor that recognizes mesothelin and contains the CD3-ζ and 4-1BB costimulatory domains (CARTmeso). The short-lived CARTmeso cells induced novel antiself antibodies and a broadly directed epitope spreading.

Priority Briefs

  • Priority Briefs
    Tumoral Immune Suppression by Macrophages Expressing Fibroblast Activation Protein-α and Heme Oxygenase-1
    James N. Arnold, Lukasz Magiera, Matthew Kraman and Douglas T. Fearon
    Cancer Immunol Res February 1 2014 2 (2) 121-126; DOI:10.1158/2326-6066.CIR-13-0150

    Arnold and colleagues identify the FAP+ CD45+ subpopulation of M2 macrophages as the major tumoral source of heme oxygenase-1 (HO-1), the inhibition of which alleviates tumoral immune suppression and arrests tumor growth. The authors suggest that targeting HO-1 may improve cancer immunotherapy.

  • Priority Briefs
    Pretreatment Serum VEGF Is Associated with Clinical Response and Overall Survival in Advanced Melanoma Patients Treated with Ipilimumab
    Jianda Yuan, Jun Zhou, Zhiwan Dong, Sapna Tandon, Deborah Kuk, Katherine S. Panageas, Philip Wong, Xinqi Wu, Jarushka Naidoo, David B. Page, Jedd D. Wolchok and F. Stephen Hodi
    Cancer Immunol Res February 1 2014 2 (2) 127-132; DOI:10.1158/2326-6066.CIR-13-0163

    Yuan, Zhou, and colleagues analyzed levels of serum VEGF in patients before and after ipilimumab therapy; they found that high pretreatment VEGF levels correlate with decreased overall survival. VEGF may serve as a biomarker for ipilimumab treatment.

Research Articles

  • Research Articles
    Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer
    James L. Gulley, Ravi A. Madan, Kwong Y. Tsang, Caroline Jochems, Jennifer L. Marté, Benedetto Farsaci, Jo A. Tucker, James W. Hodge, David J. Liewehr, Seth M. Steinberg, Christopher R. Heery and Jeffrey Schlom
    Cancer Immunol Res February 1 2014 2 (2) 133-141; DOI:10.1158/2326-6066.CIR-13-0108

    Gulley and colleagues report immune responses from patients treated with PSA-TRICOM (a vaccinia prime/fowlpox boosts vaccine regimen with vectors expressing human PSA, B7.1, ICAM-1, and LFA-3), with 57% of 104 patients developing PSA-specific immune responses and 68% with antigen spreading.

  • Research Articles
    Combined Targeting of Costimulatory (OX40) and Coinhibitory (CTLA-4) Pathways Elicits Potent Effector T Cells Capable of Driving Robust Antitumor Immunity
    William L. Redmond, Stefanie N. Linch and Melissa J. Kasiewicz
    Cancer Immunol Res February 1 2014 2 (2) 142-153; DOI:10.1158/2326-6066.CIR-13-0031-T

    Redmond and colleagues show that agonist ligation of OX40 while releasing the “brakes” on T cells via CTLA-4 blockade stimulates a unique CD4 and CD8 T-cell response that overcomes the limited efficacy of monotherapy and augments tumor immunotherapy.

  • Research Articles
    Targeting Fibroblast Activation Protein in Tumor Stroma with Chimeric Antigen Receptor T Cells Can Inhibit Tumor Growth and Augment Host Immunity without Severe Toxicity
    Liang-Chuan S. Wang, Albert Lo, John Scholler, Jing Sun, Rajrupa S. Majumdar, Veena Kapoor, Michael Antzis, Cody E. Cotner, Laura A. Johnson, Amy C. Durham, Charalambos C. Solomides, Carl H. June, Ellen Puré and Steven M. Albelda
    Cancer Immunol Res February 1 2014 2 (2) 154-166; DOI:10.1158/2326-6066.CIR-13-0027

    Wang, Lo, and colleagues report the efficacy and safety of chimeric antigen receptor T cells specific for mouse fibroblast activation protein in inhibiting the growth of subcutaneously transplanted tumors when used alone and in combination with an antitumor vaccine.

  • Research Articles
    CD4 T Cells Require ICOS-Mediated PI3K Signaling to Increase T-Bet Expression in the Setting of Anti-CTLA-4 Therapy
    Hong Chen, Tihui Fu, Woong-Kyung Suh, Dimitra Tsavachidou, Sijin Wen, Jianjun Gao, Derek Ng Tang, Qiuming He, Jingjing Sun and Padmanee Sharma
    Cancer Immunol Res February 1 2014 2 (2) 167-176; DOI:10.1158/2326-6066.CIR-13-0155

    Chen, Fu, and colleagues show that ICOS-mediated PI3K signaling is required for the expression of transcription factor T-bet, which regulates the Th1 antitumor response elicited by anti-CTLA-4 therapy, and suggest that targeting ICOS may improve Th1 antitumor responses.

  • Research Articles
    Microvesicle Cargo of Tumor-Associated MUC1 to Dendritic Cells Allows Cross-presentation and Specific Carbohydrate Processing
    Aurelia Rughetti, Hassan Rahimi, Francesca Belleudi, Chiara Napoletano, Federico Battisti, Ilaria G. Zizzari, Morena Antonilli, Filippo Bellati, Hans H. Wandall, Pierluigi Benedetti Panici, Joy M. Burchell, Mara R. Torrisi and Marianna Nuti
    Cancer Immunol Res February 1 2014 2 (2) 177-186; DOI:10.1158/2326-6066.CIR-13-0112-T

    Rughetti and colleagues show that unlike soluble glycoprotein antigens, MUC1 carried by microvesicles translocates from the endolysosomal/HLA-II to the HLA-I compartment, deglycosylates, and generates novel glycoepitopes for presentation by dendritic cells to MUC1-specific CD8+ T cells stimulating IFNγ responses.

Back to top
Cancer Immunology Research: 2 (2)
February 2014
Volume 2, Issue 2

Sign up for alerts

Jump to

Advertisement